Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary: 1. To determine the MTD of SPC2996 in combination with rituximab in patients with relapsed follicular or lymphoplasmacytic non-Hodgkin’s lymphoma 2. To determine the overall response rate (Complete Response [CR] + Partial Response [PR]) of the combination of SPC2996 and rituximab in the treatment of relapsed follicular or lymphoplasmacytic non- Hodgkin’s lymphoma 3. To determine the safety and tolerability of the combination of SPC2996 and rituximab in patients with relapsed follicular or lymphoplasmacytic non-Hodgkin’s lymphoma
Critère d'inclusion
- Follicular Lymphoma (FL); Lymphoplasmacytic (lymphoplasmacytoid) Lymphoma (LPL) / Waldenstrom’s macroglobulinemia (WM)